Cancer - Prostate(구연) (NP-061) 호르몬 단독 치료를 시행한 임상적으로 국한된 전립선 암에 있어 PSA nadir와 암 진행과의 연관성 ¹연세대학교 의과대학 비뇨의학교실 ²국립건강보험공단 일산병원 비뇨의학과 ³한양대학교 의과대학 비뇨의학교실 박지수¹, 윤민지¹, 나준채¹, 이형호², 윤영은³, 한웅규¹ Purpose: Primary androgen-deprivation therapy (PADT) is generally acknowledge as the preferred first-line treatment for most men with metastatic prostate cancer, but its use as monotherapy for clinically localized diseases remains controversial. North America and Europe guidelines generally do not recommend PADT for non-metastatic disease whereas Asian guidelines consider PADT as an option due to several reasons including relatively low morbidity from PADT for Asian men. Methods: The patients who have been diagnosed as prostate cancer and had only androgen-deprivation therapy (ADT) between January 2008 through February 2016 in Severance hospital, Sinchon were selected for retrospective analysis. Those with clinical stage T3 and T4 cancer and N1 cancer were excluded. Those patients without clinical stage, only PSA levels under 20 ng/mL were included. Results: The mean follow-up period was 63.6±19.8 months. The mean age was 74.7±6.3 years old and the mean PSA was 53.4±(323.9) ng/mL. All cause mortality was 23.0% and prostate cancer-specific mortality was 6.2%. Those with prostate cancer-specific death had shorter time for PSA nadir although it was not significant. Kaplan-Meier analysis showed that those that reached PSA nadir less than 3 months showed significantly higher cancer-specific mortality than the patients reached PSA nadir less than 3 months. Conclusion: We concluded that time to PSA nadir is significant predictors of disease progression for clinically localized prostate cancer patients with PADT. keywords : androgen-deprivation therapy, metastatic, prostate cancer